WO2003046145A3 - Materials and methods for making improved liposome compositions - Google Patents

Materials and methods for making improved liposome compositions Download PDF

Info

Publication number
WO2003046145A3
WO2003046145A3 PCT/US2002/038075 US0238075W WO03046145A3 WO 2003046145 A3 WO2003046145 A3 WO 2003046145A3 US 0238075 W US0238075 W US 0238075W WO 03046145 A3 WO03046145 A3 WO 03046145A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
liposome
materials
liposome compositions
making improved
Prior art date
Application number
PCT/US2002/038075
Other languages
French (fr)
Other versions
WO2003046145A2 (en
Inventor
Hayat Onyuksel
Israel Rubinstein
Original Assignee
Univ Illinois
Hayat Onyuksel
Israel Rubinstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Hayat Onyuksel, Israel Rubinstein filed Critical Univ Illinois
Priority to AU2002359511A priority Critical patent/AU2002359511A1/en
Publication of WO2003046145A2 publication Critical patent/WO2003046145A2/en
Publication of WO2003046145A3 publication Critical patent/WO2003046145A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are methods for treating autism, multiple sclerosis, eneuresis, Parkinson's disease, amyotrophic lateral sclerosis, brain ischemia, stroke, Cerebral palsy sleep disorder, feeding disorder and AIDS-associated dementias, using improved biologically active liposome products comprising a biologically active amphipathic compound in association with a liposome. Methods for producing the liposome products as well as methods of using the liposome products in therapeutic and diagnostic techniques are also provided.
PCT/US2002/038075 2001-11-27 2002-11-27 Materials and methods for making improved liposome compositions WO2003046145A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002359511A AU2002359511A1 (en) 2001-11-27 2002-11-27 Materials and methods for making improved liposome compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/995,263 US20020114829A1 (en) 1998-12-18 2001-11-27 Materials and methods for making improved liposome compositions
US09/995,263 2001-11-27

Publications (2)

Publication Number Publication Date
WO2003046145A2 WO2003046145A2 (en) 2003-06-05
WO2003046145A3 true WO2003046145A3 (en) 2003-10-16

Family

ID=25541596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038075 WO2003046145A2 (en) 2001-11-27 2002-11-27 Materials and methods for making improved liposome compositions

Country Status (3)

Country Link
US (1) US20020114829A1 (en)
AU (1) AU2002359511A1 (en)
WO (1) WO2003046145A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541365A (en) * 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
AU2004255379B2 (en) * 2003-07-14 2007-08-16 Mondobiotech Ag Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
FR2870741B1 (en) * 2004-05-25 2008-03-14 Coletica Sa HYDRATED LAMELLAR OR LIPOSOME PHASE CONTAINING A FATTY MONOAMINE OR A CATIONIC POLYMER PROMOTING INTERCELLULAR PENETRATION AND A COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING THE SAME.
US8491890B2 (en) 2008-07-09 2013-07-23 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
US8735828B2 (en) * 2009-01-08 2014-05-27 The Board Of Regents Of The University Of Texas System Real-time in vivo radiation dosimetry using scintillation detectors
JP4900536B2 (en) * 2009-07-02 2012-03-21 コニカミノルタホールディングス株式会社 Method for producing single cell liposomes by a two-stage emulsification method using an external aqueous phase containing a specific dispersant, and a method for producing a single cell liposome dispersion or a dry powder thereof using the method for producing single cell liposomes
US10610486B2 (en) 2010-10-28 2020-04-07 Pacira Pharmaceuticals, Inc. Sustained release formulation of a non-steroidal anti-inflammatory drug
US20170281541A1 (en) * 2014-09-05 2017-10-05 The Johns Hopkins University Liposome-based mucus-penetrating particles for mucosal delivery
WO2017048860A1 (en) * 2015-09-14 2017-03-23 Vgsk Technologies, Inc. A sterically stabilized carrier for subcutaneous, sublingual and oral therapeutics, compositions and methods for treating a mammal
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5770570A (en) * 1994-04-07 1998-06-23 Paul; Sudhir Method of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptide
US6197333B1 (en) * 1996-03-28 2001-03-06 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3220180B2 (en) * 1991-05-23 2001-10-22 三菱化学株式会社 Drug-containing protein-bound liposomes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5770570A (en) * 1994-04-07 1998-06-23 Paul; Sudhir Method of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptide
US6197333B1 (en) * 1996-03-28 2001-03-06 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions

Also Published As

Publication number Publication date
AU2002359511A1 (en) 2003-06-10
WO2003046145A2 (en) 2003-06-05
US20020114829A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
WO2003046145A3 (en) Materials and methods for making improved liposome compositions
HK1060120A1 (en) Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments constaining said compounds, and the use thereof for treating disorders of the lipid metabolism
EP1698329A4 (en) Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
AU2002216097A1 (en) Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
AU2001236904A1 (en) Deep brain stimulation system for the treatment of parkinson's disease or other disorders
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
EP1282403A4 (en) Non-invasive gene targeting to the brain
DE60024054D1 (en) MATERIALS AND METHODS OF MANUFACTURING IMPROVED MICELLA COMPOSITIONS
MY131810A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
BR0316438A (en) Erythropoietin use in heart disease
WO2003030829A3 (en) Liposome-encapsulated insulin formulations
DE60138468D1 (en) CYANOPHENOXY CARBOXYLIC ACIDS AND COMPOSITIONS FOR THE RELEASE OF ACTIVE SUBSTANCES
CA2311356A1 (en) Method for treating alzheimer's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
MA26346A1 (en) PREPARATION COMPOSITIONS CONTAINING PHYSIOLOGICALLY ACTIVE AND ACID-INSTABLE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME.
AU2002246490A1 (en) Method of treating parkinson's disease
MXPA04001419A (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease.
CA2440468A1 (en) Pregabalin lactose conjugates
BR0008739A (en) Controlled-release compositions of beta-histine
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
WO2001082892A3 (en) Liposomes containing active substances
AU8893098A (en) Immuno-modulator exhibiting anti-microbial and anti-mycobacterial activities, method for producing the same and pharmaceutical preparation for treating mycobacterioses as well as lung chronic and non specific conditions, sexually transmitted diseases and the resulting
HUP0102987A3 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP